Collegium Pharmaceutical (NASDAQ:COLL) downgraded by Zacks Investment Research


Pharmaceutical College (NASDAQ: COLLGet a rating) was downgraded by Zacks Investment Research from a “strong buy” rating to a “hold” rating in a research report delivered to clients and investors on Tuesday, Zacks.com reports.

According to Zacks, “Collegium Pharmaceutical Inc. is a specialty pharmaceutical company. It develops and markets prescription and over-the-counter pharmaceutical products for the treatment of central nervous system, respiratory and skin disorders. The Company’s product candidate consists of COL-195, COL-196, COL-171, COL-003 and COL-172 which are undergoing different clinical trials. It has developed a formulation platform technology, DETERx, for the treatment of chronic pain. Collegium Pharmaceutical Inc. is based in CUMBERLAND, USA. “

COLL has been the subject of several other research reports. Piper Sandler raised her price target on Collegium Pharmaceutical from $36.00 to $42.00 and gave the company an “overweight” rating in a Tuesday, February 22 research note. StockNews.com downgraded Collegium Pharmaceutical from a “buy” rating to a “hold” rating in a Saturday, April 2 research note. HC Wainwright raised its target price on Collegium Pharmaceutical from $26.00 to $29.00 and gave the company a “buy” rating in a Tuesday, February 15 research note. TheStreet downgraded Collegium Pharmaceutical from a “b-” rating to a “c+” rating in a Monday, April 11 research note. Finally, Cantor Fitzgerald upgraded Collegium Pharmaceutical from a “neutral” rating to an “overweight” rating and raised its price target for the stock from $18.00 to $26.00 in a Tuesday 15 research report. february. Two investment analysts gave the stock a hold rating and four gave the company a buy rating. According to MarketBeat.com, the stock currently has an average rating of “Buy” and an average price target of $31.00.

Shares of NASDAQ COLL traded at $0.16 in midday trading on Tuesday, hitting $18.25. 662,108 shares of the company were traded, against an average volume of 372,198. The company has a debt ratio of 0.99, a quick ratio of 1.07 and a current ratio of 1.13. The stock has a market capitalization of $619.09 million, a PE ratio of 10.80, a growth price-earnings ratio of 0.19 and a beta of 0.96. The company’s fifty-day moving average is $19.47 and its two-hundred-day moving average is $19.22. Collegium Pharmaceutical has a fifty-two week low of $17.07 and a fifty-two week high of $25.66.

Pharmaceutical College (NASDAQ: COLLGet a rating) last announced its results on Thursday, February 24. The specialty pharmaceutical company reported ($0.73) earnings per share for the quarter, missing the consensus estimate of $0.86 per ($1.59). Collegium Pharmaceutical achieved a net margin of 25.83% and a return on equity of 4.07%. The company posted revenue of $27.36 million for the quarter, versus a consensus estimate of $80.75 million. Research analysts expect Collegium Pharmaceutical to post earnings per share of 4.99 for the current year.

In related news, EVP Scott Dreyer sold 10,559 shares of the company in a transaction that took place on Friday, February 18. The stock was sold at an average price of $21.61, for a total transaction of $228,179.99. The transaction was disclosed in a filing with the Securities & Exchange Commission, accessible via the SEC website. 5.18% of the shares are held by insiders of the company.

Several institutional investors have recently bought and sold shares of the stock. Royal Bank of Canada increased its stake in Collegium Pharmaceutical by 17.3% during the third quarter. Royal Bank of Canada now owns 3,647 shares of the specialty pharmaceutical company valued at $72,000 after buying 537 more shares last quarter. OneAscent Financial Services LLC increased its stake in Collegium Pharmaceutical by 5.5% during the 4th quarter. OneAscent Financial Services LLC now owns 11,774 shares of the specialty pharmaceutical company valued at $220,000 after purchasing an additional 612 shares in the last quarter. California State Teachers Retirement System increased its stake in Collegium Pharmaceutical by 1.4% during the fourth quarter. California State Teachers Retirement System now owns 45,487 shares of the specialty pharmaceutical company valued at $850,000 after buying 636 additional shares last quarter. The New York State Teachers Retirement System increased its stake in shares of Collegium Pharmaceutical by 4.9% in Q3. The New York State Teachers’ Retirement System now owns 13,797 shares of the specialty pharmaceutical company valued at $272,000 after purchasing an additional 640 shares during the period. Finally, Bank of America Corp DE increased its stake in Collegium Pharmaceutical shares by 2.9% in the 4th quarter. Bank of America Corp DE now owns 24,322 shares of the specialty pharmaceutical company valued at $454,000 after purchasing an additional 681 shares during the period.

Collegium Pharmaceutical Company Profile (Get a rating)

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and markets drugs for pain management. Its portfolio includes Xtampza ER, an oral, extended-release, abuse-deterrent oxycodone formulation; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol; and Xtampza ER for the management of pain severe enough to require daily, around-the-clock, long-term opioid therapy.

See also

Get a Free Copy of Zacks’ Research Report on Collegium Pharmaceutical (COLL)

For more information on Zacks Investment Research’s research offerings, visit Zacks.com



Get news and reviews for Collegium Pharmaceutical Daily – Enter your email address below to receive a concise daily summary of breaking news and analyst ratings for Collegium Pharmaceutical and related companies with MarketBeat.com’s free daily email newsletter.